Amova Asset Management Americas Inc. Sells 701,887 Shares of Recursion Pharmaceuticals, Inc. $RXRX

Amova Asset Management Americas Inc. trimmed its stake in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 8.6% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 7,465,858 shares of the company’s stock after selling 701,887 shares during the quarter. Amova Asset Management Americas Inc.’s holdings in Recursion Pharmaceuticals were worth $36,359,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also bought and sold shares of RXRX. Vanguard Group Inc. increased its holdings in Recursion Pharmaceuticals by 10.3% in the third quarter. Vanguard Group Inc. now owns 39,780,153 shares of the company’s stock worth $194,127,000 after purchasing an additional 3,708,975 shares in the last quarter. ARK Investment Management LLC increased its holdings in Recursion Pharmaceuticals by 1.7% during the 3rd quarter. ARK Investment Management LLC now owns 33,545,499 shares of the company’s stock worth $163,702,000 after purchasing an additional 556,868 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of Recursion Pharmaceuticals by 20.7% in the second quarter. Geode Capital Management LLC now owns 7,776,408 shares of the company’s stock valued at $39,353,000 after purchasing an additional 1,332,428 shares during the last quarter. Norges Bank purchased a new stake in shares of Recursion Pharmaceuticals during the second quarter valued at approximately $16,040,000. Finally, First Trust Advisors LP raised its stake in shares of Recursion Pharmaceuticals by 82.3% during the 2nd quarter. First Trust Advisors LP now owns 1,880,290 shares of the company’s stock worth $9,514,000 after purchasing an additional 848,791 shares during the period. Institutional investors own 89.06% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. JPMorgan Chase & Co. raised Recursion Pharmaceuticals from a “neutral” rating to an “overweight” rating and increased their price objective for the company from $10.00 to $11.00 in a report on Wednesday, December 17th. Bank of America cut their price target on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a “neutral” rating for the company in a research note on Wednesday, February 25th. Morgan Stanley set a $11.00 price objective on Recursion Pharmaceuticals in a research report on Wednesday, December 17th. UBS Group set a $11.00 price objective on Recursion Pharmaceuticals in a report on Wednesday, December 17th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a report on Thursday, January 22nd. Two investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $9.40.

Recursion Pharmaceuticals Stock Up 2.8%

Shares of Recursion Pharmaceuticals stock opened at $3.64 on Thursday. The company has a market cap of $1.89 billion, a price-to-earnings ratio of -2.46 and a beta of 0.97. Recursion Pharmaceuticals, Inc. has a twelve month low of $2.98 and a twelve month high of $7.18. The company has a quick ratio of 5.50, a current ratio of 5.50 and a debt-to-equity ratio of 0.01. The company’s 50 day moving average is $4.13 and its 200 day moving average is $4.65.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its quarterly earnings data on Wednesday, February 25th. The company reported ($0.21) EPS for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.07. The company had revenue of $35.54 million during the quarter, compared to analysts’ expectations of $24.56 million. Recursion Pharmaceuticals had a negative return on equity of 63.98% and a negative net margin of 863.37%.Recursion Pharmaceuticals’s revenue for the quarter was up 671.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.53) earnings per share. Research analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current year.

Insider Activity

In related news, insider Najat Khan sold 124,403 shares of the company’s stock in a transaction on Monday, December 22nd. The shares were sold at an average price of $4.41, for a total value of $548,617.23. Following the completion of the transaction, the insider owned 611,135 shares of the company’s stock, valued at approximately $2,695,105.35. This represents a 16.91% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Blake Borgeson sold 220,000 shares of the stock in a transaction dated Tuesday, February 3rd. The stock was sold at an average price of $4.20, for a total value of $924,000.00. Following the sale, the director owned 6,429,863 shares of the company’s stock, valued at $27,005,424.60. This represents a 3.31% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 599,212 shares of company stock valued at $2,562,550 in the last ninety days. Corporate insiders own 8.43% of the company’s stock.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.